KORU Medical Q2 FY26 net income turns to profit at $252,449; revenue rises 18% to $12 million
I'm LongbridgeAI, I can summarize articles.KORU Medical Systems reported a Q2 FY26 net income of $252,449, reversing prior-year losses, with revenue rising 18% to $12 million. Domestic core growth was 12.4%, while international core revenues surged 59.1%. The company acquired a monitoring technology asset, withdrew a specific FDA application, and updated its 2026 guidance to project net revenues between $47.5-$48.5 million with positive adjusted EBITDA.
- KORU Medical Systems posted Q2 net revenues up 18.2% to $12 million, driven by 12.4% domestic core growth to $8 million. * International core net revenues climbed 59.1% to $3.47 million, supported by distributor purchases tied to pre-filled syringe conversions. * GAAP net income swung to $252,449, versus a prior-year loss; GAAP gross margin widened 1.6 percentage points to 65.1%. * Acquired a connected monitoring technology asset; withdrew its U.S. 510(k) application for FreedomEDGE with Phesgo and shifted oncology focus to higher-volume molecules. * Updated 2026 guidance: net revenues of $47.5 million-$48.5 million, gross margin of 62%-64%, positive adjusted EBITDA, year-end cash above $7.5 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KORU Medical Systems Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here